Outcome of Board Meeting of Suven Life Sciences Limited held on May 13, 2026
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences Limited held its Board Meeting on May 13, 2026, approving the audited financial results for FY2026. The company reported standalone total income of Rs. 2,102.52 lakhs (up 21% from Rs. 1,738.17 lakhs), but posted a standalone loss before tax of Rs. 5,486.28 lakhs (vs Rs. 4,707.98 lakhs loss in FY2025). On a consolidated basis, the loss was much larger at Rs. 27,634.41 lakhs due to heavy R&D spending at the US subsidiary Suven Neurosciences Inc. The company's EPS stood at Rs. (2.41) on standalone and Rs. (12.13) on consolidated basis. The Board also scheduled the 37th AGM for August 25, 2026 via video conferencing. Additionally, the Board noted that BSE had waived fines imposed for prior period non-compliance with Regulation 19 of SEBI LODR, while the NSE waiver application outcome is still pending. The auditors issued an unmodified (clean) opinion on the financial statements.
The company continues to burn cash due to heavy R&D investments, with losses widening significantly on consolidated basis. The pending NSE compliance waiver and past regulatory fines may raise concerns among investors about governance standards. However, the clean audit opinion and substantial capital raised (Rs. 76,433 lakhs from warrant conversions) provide some comfort regarding financial reporting integrity.